Valneva SE (INRLF)
OTCMKTS · Delayed Price · Currency is USD
5.75
0.00 (0.00%)
Aug 22, 2025, 4:00 PM EDT
Valneva SE Revenue
Valneva SE had revenue of 48.33M EUR in the quarter ending June 30, 2025, with 26.98% growth. This brings the company's revenue in the last twelve months to 196.33M, up 25.47% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
196.33M EUR
Revenue Growth
+25.47%
P/S Ratio
4.36
Revenue / Employee
275.35K EUR
Employees
713
Market Cap
1.01B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Glass House Brands | 221.55M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 105.45M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Valneva SE News
- 5 days ago - Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older - GlobeNewsWire
- 11 days ago - Valneva SE 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 11 days ago - Valneva SE (VALN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Valneva reports 1H results; reaffirms FY outlook - Seeking Alpha
- 11 days ago - Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 16 days ago - FDA lifts pause on Valneva's chikungunya vaccine in elderly - Seeking Alpha
- 16 days ago - Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information - GlobeNewsWire
- 25 days ago - AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate - Business Wire